{"schema_version":"secwatch.filing_event.v1","accession":"0001378325-26-000019","form_type":"8-K","ticker":"CV","cik":"0001378325","company_name":"CapsoVision, Inc","filed_at":"2026-05-14T20:08:08+00:00","discovered_at":"2026-05-14T20:10:11.182821+00:00","generated_at":"2026-05-14T20:59:08.579308+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs","bullets":["Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.","Gross margin 48% vs 54% YoY due to impact of U.S. trade policies and tariffs.","Operating expenses $8.4M, up $1.5M from CMOS sensor development with Canon and Colon clinical trials.","Cash $17.9M; completed $14M PIPE financing on March 16, 2026.","Pipeline: AI-assisted reading feature on track for mid-2026 FDA clearance; CapsoCam Colon 510(k) submission Q3 2026; pancreatic cancer study enrolled first patient May 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001378325-26-000019","json":"https://secwatch.observer/filing/0001378325-26-000019.json","markdown":"https://secwatch.observer/filing/0001378325-26-000019.md","text":"https://secwatch.observer/filing/0001378325-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/0001378325-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/cv-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:59:08.579308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"105f13bf0d81b8fe5a331c6866eb98663f4b94f3","claim":"CapsoVision, Inc reported the fiscal quarter ended March 31, 2026 results: revenue $2.8 million.","evidence_excerpt":"and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026. Recent Highlights • Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025. • Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/0001378325-26-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2026"},{"label":"Revenue","value":"$2.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}